Mesenchymal Stem Cell Therapy in Joint Disease

  1. Gregory Bock Organizer and
  2. Jamie Goode
  1. Frank P. Barry

Published Online: 7 OCT 2008

DOI: 10.1002/0470867973.ch7

Tissue Engineering of Cartilage and Bone: Novartis Foundation Symposium 249

Tissue Engineering of Cartilage and Bone: Novartis Foundation Symposium 249

How to Cite

Barry, F. P. (2003) Mesenchymal Stem Cell Therapy in Joint Disease, in Tissue Engineering of Cartilage and Bone: Novartis Foundation Symposium 249 (eds G. Bock and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470867973.ch7

Author Information

  1. Osiris Therapeutics Inc., 2001 Aliceanna Street, Baltimore, MD 21231, USA

Publication History

  1. Published Online: 7 OCT 2008
  2. Published Print: 11 MAR 2003

Book Series:

  1. Novartis Foundation Symposia

Book Series Editors:

  1. Novartis Foundation

ISBN Information

Print ISBN: 9780470844816

Online ISBN: 9780470867976

SEARCH

Summary

Mesenchymal stem cells have the capacity to differentiate into a variety of connective tissue cells including bone, cartilage, tendon, muscle and adipose tissue. These multipotent cells have been isolated from bone marrow and from other adult tissues including skeletal muscle, fat and synovium. Because of their multipotentiality and capacity for self renewal adult stem cells may represent units of active regeneration of tissues damaged as a result of trauma or disease. In certain degenerative diseases such as osteoarthritis (OA) stem cells are depleted, and have reduced proliferative capacity and reduced ability to differentiate. The delivery of stem cells to these individuals may therefore enhance repair or inhibit the progressive destruction of the joint. We have developed methods for the delivery of mesenchymal stem cell preparations taken from bone marrow to the injured knee joint. This treatment has the potential to stimulate regeneration of cartilage and retard the progressive destruction of the joint that typically occurs following injury.